DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Metastatic Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Metastatic Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Breast Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Metastatic Breast Cancer Pipeline Report
To explore more information on the latest breakthroughs in the Metastatic Breast Cancer Pipeline treatment landscape of the report, click here @ Metastatic Breast Cancer Pipeline Outlook
Metastatic Breast Cancer Overview
Metastatic breast cancer (also called stage IV) is breast cancer that has spread to another part of the body, most commonly the liver, brain, bones, or lungs. The symptoms of metastatic breast cancer can vary greatly depending on the location of the cancer. This section covers the symptoms of breast cancer that has spread to the bone, lung, brain, and liver, and the tests used to diagnose metastatic breast cancer.
Recent Developmental Activities of Metastatic Breast Cancer Treatment Landscape
Request a sample and discover the recent advances in Metastatic Breast Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Breast Cancer Treatment Landscape
Metastatic Breast Cancer Emerging Drugs
Giredestrant: Roche
Giredestrant is a next generation investigational Selective estrogen receptor degrader (SERD), designed to fully block ER signalling with robust receptor occupancy. Oestrogen encourages HR-positive breast cancer cells to grow by attaching to the ER. Giredestrant works by blocking this receptor to prevent the action of oestrogen, and in the process causes the receptor to be degraded. This investigational medicine has also shown efficacy regardless of ESR1 mutation status (mutations in the ESR1 gene are important mechanisms of resistance to hormone therapy).
Disitamab Vedotin: RemeGen
Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells.
EndoTAG®-1 (SB05): SynCore Biotechnology
SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the supply to not activated endothelial cells of healthy tissue. By doing this, SB05 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth.
Stenoparib (2X-121): Allarity Therapeutics
Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. Given its novel mechanism of action and ability to cross the blood brain barrier (BBB), plus its associated DRP®, stenoparib is poised to yield improved efficacy, lower toxicity, and lower drug resistance compared the other late-stage or marketed PARP inhibitors.
Metastatic Breast Cancer Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Metastatic Breast Cancer. The companies which have their Metastatic Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Roche.
For further information, refer to the detailed Metastatic Breast Cancer Unmet Needs, Metastatic Breast Cancer Market Drivers, and Metastatic Breast Cancer Market Barriers, click here for Metastatic Breast Cancer Ongoing Clinical Trial Analysis
Metastatic Breast Cancer Phases
Scope of the Metastatic Breast Cancer Pipeline Report
Dive deep into rich insights for drugs for Metastatic Breast Cancer Market Drivers and Metastatic Breast Cancer Market Barriers, click here @ Metastatic Breast Cancer Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Metastatic Breast Cancer Mergers and acquisitions, Metastatic Breast Cancer licensing activities @ Metastatic Breast Cancer Emerging Drugs and Recent Trends
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight